Study of Palbociclib in Children with Brain Tumors
Author Information
Author(s): Panetta John C., Selvo Nicholas S., Mater David Van, Stewart Clinton F.
Primary Institution: St. Jude Children’s Research Hospital
Hypothesis
The study aims to characterize the pharmacokinetics and pharmacodynamics of palbociclib in children with recurrent, progressive, or refractory brain tumors.
Conclusion
Palbociclib pharmacokinetics and pharmacodynamics were adequately characterized in this patient population, with no unexpected adverse reactions noted.
Supporting Evidence
- The study included 34 patients aged 4.9 to 21.6 years.
- Palbociclib was well tolerated with no unexpected adverse reactions.
- 49% of individuals were expected to have grade 3 or greater neutropenia at a dosage of 75 mg/m2.
Takeaway
This study looked at how a cancer drug called palbociclib works in kids with brain tumors, finding it to be safe and effective.
Methodology
The study involved a phase 1 clinical trial with pharmacokinetic and pharmacodynamic analyses conducted on 34 patients.
Potential Biases
The study may have bias due to the small number of patients and the exclusion of some data points.
Limitations
The study had a relatively small sample size and lacked external model validation.
Participant Demographics
Participants were aged 4.9 to 21.6 years, with a majority being Caucasian.
Statistical Information
P-Value
0.0066
Statistical Significance
p = 0.0066
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website